All Stories

  1. Quantitative cytokine level of TNF-α, IFN-γ, IL-10, TGF-β and circulating Epstein-Barr virus DNA load in individuals with acute Malaria due to P. falciparum or P. vivax or double infection in a Malaria endemic region in Indonesia
  2. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis
  3. Epstein-Barr DNA in advanced pediatric nasopharyngeal cancer
  4. PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach
  5. Rapid nasopharyngeal brush-smear cytology with Epstein-Barr virus DNA load and viral marker analysis for detection of nasopharyngeal carcinoma
  6. Cytolytic Epstein-Barr Virus Reactivation Therapy for EBV-Associated Gastric Carcinoma
  7. Correction: Identification of a Novel, EBV-based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan
  8. Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom
  9. Reactivation of Epstein–Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn 2+ -chelating function
  10. Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization
  11. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections
  12. Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma
  13. Differences in the Epstein-Barr virus gp350 IgA antibody response are associated with increased risk for co-infection with a second strain of EBV
  14. Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases
  15. Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
  16. Epstein–Barr Virus Gene BARF1 Expression is Regulated by the Epithelial Differentiation Factor ΔNp63α in Undifferentiated Nasopharyngeal Carcinoma
  17. Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome
  18. Correction: Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling
  19. Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling
  20. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan
  21. Detecting EBV in Nasal or Nasopharyngeal Swabs of NPC Patients
  22. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model
  23. Seroprevalence of IgA anti Epstein-Barr virus is high among family members of nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and neck area
  24. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression
  25. Natural Variation of Epstein-Barr Virus Genes, Proteins, and Primary MicroRNA
  26. Quantitative multi-target RNA profiling in Epstein-Barr virus infected tumor cells
  27. Epstein-Barr–negative MS: a true phenomenon?
  28. High Levels of EBV-Encoded RNA 1 (EBER1) Trigger Interferon and Inflammation-Related Genes in Keratinocytes Expressing HPV16 E6/E7
  29. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin
  30. Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein
  31. A2.09 Longitudinal EBV antibody profiling in sle patients reveals patients with lupus nephritis
  32. Sensing of latent EBV infection through exosomal transfer of 5′pppRNA
  33. The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells
  34. Possible contributing role of Epstein-Barr virus (EBV) as a cofactor in human papillomavirus (HPV)-associated cervical carcinogenesis
  35. A single nucleotide polymorphism in the Epstein-Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma
  36. Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with Plasmodium falciparum Malaria during Pregnancy
  37. Romidepsin induces cell death in cancers associated with Epstein-Barr virus
  38. Abstract 2716: Epstein-Barr virus-encoded BARF1 downregulates SMAD4 and increases miR-146a in gastric carcinoma cells
  39. Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group
  40. Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma
  41. Telomerase Activity Impacts on Epstein-Barr Virus Infection of AGS Cells
  42. Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study
  43. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease
  44. Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes
  45. Epstein-Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells
  46. Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
  47. Nontemplated Nucleotide Additions Distinguish the Small RNA Composition in Cells from Exosomes
  48. Action of HDAC and proteasome inhibitors in EBV-driven B cell lymphoma
  49. Current Status of Cancer Care for Young Patients with Nasopharyngeal Carcinoma in Jakarta, Indonesia
  50. Hypothesis: A role for EBV-induced molecular mimicry in Parkinson's disease
  51. Epstein-Barr virus viral load and serology in childhood non-Hodgkin's lymphoma and chronic inflammatory conditions in Uganda: Implications for disease risk and characteristics
  52. P0126 Cytolytic virus activation therapy for epstein-barr virus driven tumours
  53. Epstein-Barr Virus Serology as a Potential Screening Marker for Nasopharyngeal Carcinoma among High-Risk Individuals from Multiplex Families in Taiwan
  54. BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator
  55. Epstein-Barr Virus-Encoded BARF1 Promotes Proliferation of Gastric Carcinoma Cells through Regulation of NF- B
  56. Primary Treatment Results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia
  57. Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment
  58. Lower mortality from nasopharyngeal cancer in The Netherlands since 1970 with differential incidence trends in histopathology
  59. Virus-modified exosomes for targeted RNA delivery; A new approach in nanomedicine
  60. Analysis of Viral MicroRNA Exchange via Exosomes In Vitro and In Vivo
  61. Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma
  62. Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international reference laboratory
  63. Epstein-Barr Virus-Encoded BARF1 Protein is a Decoy Receptor for Macrophage Colony Stimulating Factor and Interferes with Macrophage Differentiation and Activation
  64. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells
  65. Development of a Non-Invasive Method, Multiplex Methylation Specific PCR (MMSP), for Early Diagnosis of Nasopharyngeal Carcinoma
  66. Persistence of Epstein-Barr Virus in Self-Reactive Memory B Cells
  67. Epstein-Barr Virus Transcription Activator R Upregulates BARF1 Expression by Direct Binding to Its Promoter, Independent of Methylation
  68. Cytolytic Virus Activation Therapy for Epstein-Barr Virus-Driven Tumors
  69. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence,signs, and symptoms at presentation
  70. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors
  71. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia
  72. Short-Term Effect of Different Teaching Methods on Nasopharyngeal Carcinoma for General Practitioners in Jakarta, Indonesia
  73. Activation of lytic cycle of Epstein‐Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma
  74. Early Age at Time of Primary Epstein–Barr Virus Infection Results in Poorly Controlled Viral Infection in Infants From Western Kenya: Clues to the Etiology of Endemic Burkitt Lymphoma
  75. Intracellular signaling controlled by the endosomal-exosomal pathway
  76. Variable EBV DNA Load Distributions and Heterogeneous EBV mRNA Expression Patterns in the Circulation of Solid Organ versus Stem Cell Transplant Recipients
  77. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions
  78. Viral miRNAs exploiting the endosomal–exosomal pathway for intercellular cross-talk and immune evasion
  79. Contributions of the Epstein-Barr Virus EBNA1 Protein to Gastric Carcinoma
  80. A Novel Persistence Associated EBV miRNA Expression Profile Is Disrupted in Neoplasia
  81. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria
  82. Can an online clinical data management service help in improving data collection and data quality in a developing country setting?
  83. LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation
  84. A human tumor virus extends its reach
  85. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls
  86. Epstein–Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin
  87. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population
  88. Purified Hexameric Epstein-Barr Virus-Encoded BARF1 Protein for Measuring Anti-BARF1 Antibody Responses in Nasopharyngeal Carcinoma Patients
  89. Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph
  90. Combination of Epstein–Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease
  91. Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV‐6 in post‐infective fatigue syndrome
  92. Exosomes
  93. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis
  94. Functional delivery of viral miRNAs via exosomes
  95. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: Regulation of infection and phenotypic characterization
  96. Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30
  97. Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study
  98. Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma
  99. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis
  100. Epstein-Barr Virus Latent Membrane Protein 1 is not Associated with Vessel Density nor with Hypoxia Inducible Factor 1 Alpha Expression in Nasopharyngeal Carcinoma Tissue
  101. A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation
  102. 8528 Epstein-Barr virus quantification and aberrant host DNA methylation pattern as marker for nasopharyngeal carcinoma in non-invasive nasopharyngeal brushings
  103. Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle
  104. Epstein-Barr Virus Latency in B Cells Leads to Epigenetic Repression and CpG Methylation of the Tumour Suppressor Gene Bim
  105. Serological evidence for long-term epstein-barr virus reactivation in children living in a holoendemic malaria region of Kenya
  106. Two-Step Epstein-Barr Virus Immunoglobulin A Enzyme-Linked Immunosorbent Assay System for Serological Screening and Confirmation of Nasopharyngeal Carcinoma
  107. O.1.5 LMP1 trafficking via the antigen presentation route
  108. P.021 Native conformation and wild-type sequence of Epstein–Barr virus protein BARF1 are essential for humoral immune responses to BARF1 in nasopharyngeal carcinoma patients
  109. O.5.7 Detailed characterisation of Epstein–Barr virus (EBV) infected cells in the circulation of organ transplant recipients with persistent high EBV DNA loads
  110. Comprehensive Profiling of Epstein-Barr Virus MicroRNAs in Nasopharyngeal Carcinoma
  111. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape
  112. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma
  113. Reconstitution of Nasopharyngeal Carcinoma-Type EBV Infection Induces Tumorigenicity
  114. Dried-Blood Sampling for Epstein-Barr Virus Immunoglobulin G (IgG) and IgA Serology in Nasopharyngeal Carcinoma Screening
  115. The DNase of Gammaherpesviruses Impairs Recognition by Virus-Specific CD8+ T Cells through an Additional Host Shutoff Function
  116. Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression
  117. Aberrant Epstein–Barr virus persistence in HIV carriers is characterized by anti-Epstein–Barr virus IgA and high cellular viral loads with restricted transcription
  118. Host shutoff during productive Epstein–Barr virus infection is mediated by BGLF5 and may contribute to immune evasion
  119. Native early antigen of Epstein–Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma
  120. Epstein-Barr virus infection and risk of lymphoma: Immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls
  121. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9
  122. Noninvasive diagnosis of nasopharyngeal carcinoma: Nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA
  123. Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field ...
  124. Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy
  125. The antibody 2B4 directed against the Epstein–Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers
  126. Morphological Evidence of an Activated Cytotoxic T-Cell Infiltrate in EBV-Positive Gastric Carcinoma Preventing Lymph Node Metastases
  127. Epstein-Barr Virus mRNA Export Factor EB2 Is Essential for Intranuclear Capsid Assembly and Production of gp350
  128. In Nasopharyngeal Carcinoma Cells, Epstein-Barr Virus LMP1 Interacts with Galectin 9 in Membrane Raft Elements Resistant to Simvastatin
  129. Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia
  130. Role of Sexual Behavior in the Acquisition of Asymptomatic Epstein-Barr Virus Infection
  131. Human Cytomegalovirus Infection of a Severe-Burn Patient: Evidence for Productive Self-Limited Viral Replication in Blood and Lung
  132. Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome
  133. Expression and analysis of the Epstein-Barr virus BARF1-encoded protein from a tetracycline-regulatable adenovirus system
  134. Epstein-Barr virus (EBV)-encodedBARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression
  135. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia
  136. Epstein-Barr Virus Infection in Ex Vivo Tonsil Epithelial Cell Cultures of Asymptomatic Carriers
  137. The Amino Terminus of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Contains AT Hooks That Facilitate the Replication and Partitioning of Latent EBV Genomes by Tethering Them to Cellular Chromosomes
  138. Cytomegalovirus (CMV) Inactivation in Breast Milk: Reassessment of Pasteurization and Freeze-Thawing
  139. Molecular Diversity of Epstein‐Barr Virus IgG and IgA Antibody Responses in Nasopharyngeal Carcinoma: A Comparison of Indonesian, Chinese, and European Subjects
  140. Molecular Evidence for Rhesus Lymphocryptovirus Infection of Epithelial Cells in Immunosuppressed Rhesus Macaques
  141. EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node Involvement
  142. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cellsin vivo
  143. In vivo transcription of the Epstein-Barr virus (EBV) BamHI-A region without associated in vivo BARF0 protein expression in multiple EBV-associated disorders
  144. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate
  145. Localization of the Epstein-Barr virus protein LMP 1 to exosomes
  146. Prenatal Diagnosis of Congenital Human Cytomegalovirus Infection in Amniotic Fluid by Nucleic Acid Sequence-Based Amplification Assay
  147. Genetic Diversity: Frameshift Mechanisms Alter Coding of a Gene (Epstein-Barr Virus LF3 Gene) That Contains Multiple 102-Base-Pair Direct Sequence Repeats
  148. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial
  149. Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob
  150. Pathogenic roles for Epstein–Barr virus (EBV) gene products in EBV-associated proliferative disorders
  151. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease
  152. Epstein–Barr virus replication in tongue epithelial cells
  153. Comparison of Quantitative Competitive PCR with LightCycler-Based PCR for Measuring Epstein-Barr Virus DNA Load in Clinical Specimens
  154. Molecular diagnosis of viral infections in renal transplant recipients
  155. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease
  156. A Rapid and Reliable Enzyme Immunoassay PCR-Based Screening Method to Identify EBV-Carrying Gastric Carcinomas
  157. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation
  158. Detection of late pp67-mRNA by NASBA in peripheral blood for the diagnosis of human cytomegalovirus disease in AIDS patients
  159. Absence of elevated anti- -synuclein and anti-EBV latent membrane protein antibodies in PD
  160. High Epstein–Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology
  161. Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2
  162. Multiplex real-time NASBA for monitoring expression dynamics of human cytomegalovirus encoded IE1 and pp67 RNA
  163. TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMAB
  164. Role of Epstein-Barr Virus DNA Load Monitoring in Prevention and Early Detection of Post-transplant Lymphoproliferative Disease
  165. High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent
  166. Different profiles of cytomegalovirus RNA transcripts and anti-cytomegalovirus IgM antibodies in renal transplant recipients
  167. Human Cytomegalovirus Immediate‐Early Messenger RNA in Blood of Pregnant Women with Primary Infection and of Congenitally Infected Newborns
  168. Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses
  169. Expression Dynamics of Human Cytomegalovirus Immune Evasion GenesUS3, US6,andUS11in the Blood of Lung Transplant Recipients
  170. Quantitative competitive NASBA for measuring mRNA expression levels of the immediate early 1, late pp67, and immune evasion genes US3, US6 and US11 in cells infected with human cytomegalovirus
  171. Toward Standardization of Epstein-Barr Virus DNA Load Monitoring: Unfractionated Whole Blood as Preferred Clinical Specimen
  172. Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders
  173. Is Epstein-Barr virus present in the CNS of patients with MS?
  174. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients
  175. Functional CD4+ and CD8+ T-Cell Responses Induced by Autologous Mitomycin C Treated Epstein–Barr Virus Transformed Lymphoblastoid Cell Lines
  176. Patients at risk for post-transplant lymphoproliferative disease can be identified in the first months after lung transplantation by quantitative-competitive-EBV-PCR
  177. Direct Quantification of Human Cytomegalovirus Immediate-Early and Late mRNA Levels in Blood of Lung Transplant Recipients by Competitive Nucleic Acid Sequence-Based Amplification
  178. Use of CMV transcripts for monitoring of CMV infections in transplant recipients
  179. Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells
  180. Bioreactor-Scale Production and One-Step Purification of Epstein–Barr Nuclear Antigen 1 Expressed in Baculovirus-Infected Insect Cells
  181. Human Cytomegalovirus Virions Differentially Incorporate Viral and Host Cell RNA during the Assembly Process
  182. EVALUATION OF HUMAN CYTOMEGALOVIRUS GENE EXPRESSION IN THORACIC ORGAN TRANSPLANT RECIPIENTS USING NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION
  183. Hairy Leukoplakia: an Unusual Combination of Transforming and Permissive Epstein-Barr Virus Infections
  184. Efficacy of ionizing radiation combined with adenoviral p53 therapy in EBV‐positive nasopharyngeal carcinoma
  185. Direct Immunosuppressive Effects of EBV-Encoded Latent Membrane Protein 1
  186. All infiltrating T-lymphocytes in Hodgkin's disease express immunohistochemically detectable T-cell receptor zeta-chains in situ
  187. Expression of the transforming Epstein-Barr virus BARF1 gene in EBV-carrying gastric adenocarcinomas
  188. Early detection of cytomegalovirus in renal transplant recipients: comparison of PCR, NASBA, pp65 antigenemia, and viral culture
  189. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease
  190. Sensitive detection of cytomegalovirus infection in transplant recipients using nucleic acid sequence-based amplification
  191. Quantitative immunohistochemical analysis of cytokine profiles in Epstein–Barr virus‐positive and ‐negative cases of Hodgkin's disease
  192. Efficacy of ionizing radiation combined with adenoviralp53 therapy in EBV-positive nasopharyngeal carcinoma
  193. EARLY DETECTION OF HUMAN CYTOMEGALOVIRUS INFECTION AFTER KIDNEY TRANSPLANTATION BY NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION1
  194. Restricted Low‐Level Human Antibody Responses against Epstein‐Barr Virus (EBV)–Encoded Latent Membrane Protein 1 in a Subgroup of Patients with EBV‐Associated Diseases
  195. Direct quantification of human cytomegalovirus (HCMV) immediate early and late mRNA levels in the blood of HCMV-infected individuals using competetive NASBA
  196. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases [published erratum appears in Mol Pathol 1999 Oct;52(5):305]
  197. Nucleic acid sequence-based amplification: a new technique for monitoring cytomegalovirus infection in transplant recipients
  198. Diagnostic Value of Nucleic-Acid-Sequence- Based Amplification for the Detection of Cytomegalovirus Infection in Renal and Liver Transplant Recipients
  199. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma
  200. Evaluation of a new method for early detection of active cytomegalovirus infections. A study in kidney transplant recipients
  201. Physical association between the EBV protein EBNA-1 and P32/TAP/hyaluronectin
  202. Physical Association between the EBV Protein EBNA-1 and P32/TAP/Hyaluronectin
  203. A Major DNA Binding Protein Encoded by BALF2 Open Reading Frame of Epstein–Barr Virus (EBV) Forms a Complex with Other EBV DNA-Binding Proteins: DNAase, EA-D, and DNA Polymerase
  204. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.
  205. P32/TAP, a Cellular Protein That Interacts with EBNA-1 of Epstein–Barr Virus
  206. Fine-mapping of human and mouse/rat antibody binding to Epstein-Barr virus nuclear antigen-1 (EBNA-1): Linear and conformational epitopes
  207. Epstein Barr virus specific antibody patterns in lung transplant recipients with post transplant lymphoproliferative disease
  208. Epstein Barr virus encoded latent membrane protein (LMP-1) escapes from humoral immune control
  209. Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.
  210. Molecular species of hepadnavirus core and envelope polypeptides in hepatocyte plasma membrane of woodchucks with acute and chronic viral hepatitis,
  211. Detection of hepatitis C virus antigen by immuno-histochemical staining: a histological marker of hepatitis C virus infection
  212. Expression of epstein-barr-virus-related nuclear antigens and B-cell markers in lymphomas of SIV-immunosuppressed monkeys
  213. Epstein-Barr Virus Gene Expression in Oral Hairy Leukoplakia
  214. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex
  215. Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells
  216. Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides
  217. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis
  218. Development of an antibody-capture IgM-enzyme-linked immunosorbent assay for diagnosis of acute epstein-barr virus infections
  219. A sensitive enzyme-linked immunosorbent assay for the detection of herpes simplex virus antigens
  220. Killing of Human Cytomegalovirus-Infected Fibroblasts by Antiviral Antibody and Complement
  221. CYTOMEGALOVIRUS IMMUNITY IN ALLOGENEIC MARROW GRAFTING1
  222. HLA-DRw6 as a risk factor for active cytomegalovirus but not for herpes simplex virus infection after renal allograft transplantation.
  223. Cytomegalovirus (CMV)-infections and hosts’ immunoregulation in liver transplantation
  224. A Stimulatory Role for Cytomegalovirus (CMV) Antibodies in CMV-Specific Lymphocyte Proliferation in vitro
  225. An in vitro System to Study Interactions between Bacteria and Epithelial Cells at the Molecular Level
  226. Quantitative Detection of Epstein-Barr Virus DNA in Clinical Specimens by Rapid Real-Time PCR Targeting a Highly Conserved Region of EBNA-1
  227. Profiling of Epstein-Barr Virus Latent RNA Expression in Clinical Specimens by Gene-Specific Multiprimed cDNA Synthesis and PCR
  228. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate (Glivec)